FDA grants expanded approval for Bristol Myers Squibb anemia therapy - NJBIZ

“The approval of Reblozyl in the first-line treatment of anemia for patients with lower-risk MDS represents a crucial step in making transfusion independence possible for more patients," said Tracey Iraca, executive director of the MDS Foundation.

Crow Holdings completes $164M sale of Franklin Township logistics property - NJBIZ

U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis

Solidia Technologies names new CTO - NJBIZ

U.S. FDA approves new Bristol Myers cancer immunotherapy

Young adults, teens one-third of new COVID cases among recent NJ surge - NJBIZ

Bristol Myers (BMY) Gets FDA Nod for Reblozyl Label Expansion

FDA expands Reblozyl approval to first-line use - Drug Discovery World (DDW)

FDA grants expanded approval for Bristol Myers Squibb anemia therapy - NJBIZ

FDA Approves Expansion for BMS' Reblozyl as First-Line Anemia Treatment

American Dream's luxury retail wing opens this September - NJBIZ

FDA Grants Expanded Approval to Bristol Myers' Reblozyl for MDS Treatment

Young adults, teens one-third of new COVID cases among recent NJ surge - NJBIZ

NJ companies give, and get, COVID-19 donations - NJBIZ

U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma